Dermaseal Labs
DermaSeal Labs is a translational research and product development company advancing the science of compromised skin. By combining rigorous scientific research with practical clinical applications, we develop technologies that improve outcomes across dermatology, wound care, and regenerative medicine.
Innovation Platform
Research Areas
Research AreasBalanced Wound Moisture
Developing technologies that maintain an optimal wound moisture environment to support healing and reduce complications.
Differentiated Antimicrobial Technologies
Developing next-generation antimicrobials that control bioburden while supporting the healing environment.
Autolytic Debridement
Developing technologies that support the body's natural removal of non-viable tissue to prepare the wound bed for healing.
Medical Device | 510(k) CDRH
Dermaseal LITERx
FIRST-LINE TOPICAL ANTIMICROBIAL
Investigational wound management ointment under development for clinical wound care. Designed with a biocompatible wound matrix to support autolytic debridement and balanced wound moisture, with clinical performance currently under evaluation.
Medical Device | 510(k) CDRH
Dermaseal LITEOTC
ADVANCED WOUND MANAGEMENT
Investigational wound healing ointment being developed for everyday wound care. Features a precision applicator for controlled, hygienic application while supporting a balanced wound healing environment.
Rx Drug | 505(b)(2) CDER
Dermaseal MAX
Chronic Wound Therapy
Investigational dual-format therapy combining a topical ointment and powder for advanced wound management. Currently in clinical development for chronic wound applications, including diabetic foot ulcers and burn wound debridement.
